Corient Private Wealth
KPTI icon

Corient Private Wealth’s Karyopharm Therapeutics KPTI Stock Holding History

Corient Private Wealth’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,367
Closed -$13.9K – 2372
2024
Q4 		$13.9K Sell
1,367
-39
-3% -$472 ﹤0.01% 2315
2024
Q3 		$17.5K Buy
1,406
+499
+55% +$6.2K ﹤0.01% 2434
2024
Q2 		$11.8K Sell
907
-20
-2% -$331 ﹤0.01% 2303
2024
Q1 		$21K Sell
927
-6
-0.6% -$105 ﹤0.01% 2261
2023
Q4 		$12.1K Buy
+933
New +$12.6K ﹤0.01% 2232

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Corient Private Wealth's KPTI Position: Q1 2025 in Review

Corient Private Wealth sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 1,367 shares — an estimated $13.9K sold.

Corient Private Wealth first reported a position in KPTI in Q4 2023 and held it in 5 quarters. The position peaked at $21K in Q1 2024. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Corient Private Wealth reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Corient Private Wealth sold 1,367 Karyopharm Therapeutics shares in Q1 2025, an estimated $13.9K.
  • Corient Private Wealth first reported a position in Karyopharm Therapeutics in Q4 2023 and held it in 5 quarters.
  • Corient Private Wealth's Karyopharm Therapeutics position peaked at $21K in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Corient Private Wealth's 13F filing for Q1 2025, filed 14 May 2025.